Objective: To study neurologic complications after heart transplant.
H
EART TRANSPLANT IS A therapeutic option for end-stage heart failure. Approximately 24 000 patients have undergone heart transplant in the United States during the last 10 years. 1 In this study, we investigated the prevalence of neurologic complications in 313 heart transplant recipients with up to 18 years of follow-up.
METHODS
We retrospectively studied patients who underwent heart transplant in the Mayo Clinic cardiac transplant program from January 1, 1988 , through October 31, 2006. The following sources of information were used: Mayo Clinic Transplant Database, Diagnostic Index Database, paper and electronic medical records, records of the Mayo Clinic clinical laboratories, and results of cranial imaging. Data were extracted on patients' history, baseline characteristics, perioperative period (between heart transplant and discharge), histopathological stenosis of coronary arteries of explanted hearts (grades I-IV), and occurrence of neurologic events. The entire spectrum of potentially neurologic complications was scored, including pain, depression, and anxiety. Patient characteristics were recorded according to the judgment of the treating physician.
Immunosuppressive programs were recorded at 2 and 6 months and 2 and 6 years after transplant. Functional outcome was graded according to the Glasgow Outcome Scale at discharge 1 year after transplant. A score of 1 on this scale indicates death; a score of 2, a vegetative state (the patient is unable to inter-act with the environment); a score of 3, severe disability (the patient is unable to live independently but can follow commands); a score of 4, moderate disability (the patient is capable of living independently but unable to return to work or school); and a score of 5, mild or no disability (the patient is able to return to work or school). A favorable outcome was defined as a score of 5, and an unfavorable outcome was defined as a score of 1 to 4; this scale does not define whether deficits that might prevent a child from returning to school or an adult to work were on a neurologic basis.
This study was approved by the institutional review board of the Mayo Clinic. Two patients who underwent transplant and gave no authorization concerning medical record research studies were excluded.
Data were summarized using means and standard deviations for numeric variables or medians with interquartile ranges (IQRs) as appropriate, and counts and percentages were used for categorical variables. Parametric (t test or analysis of variance) and nonparametric (Mann-Whitney U test or Kruskall-Wallis H test) tests as appropriate were used to identify differences between groups in continuous outcomes, and 2 tests were used to compare categorical outcomes. The associations between baseline variables, neurologic complications, and mortality were assessed using Cox regression. Predictors changing after baseline were included in the Cox model as time-dependent predictors, eg, neurologic complications, when predicting mortality. The Kaplan-Meier method adapted to account for the competing risk of death was used to describe cumulative incidences for neurologic complications, and the standard Kaplan-Meier method was used for describing mortality incidences. Tests were performed at the 5% level and confidence limits constructed at the 95% level. Table 1 ). The proportion of transplant recipients with ischemic cardiomyopathy decreased over time, whereas the proportion of patients in the miscellaneous group increased. This miscellaneous group included patients with cardiomyopathy after radiation therapy or chemotherapy, valvular disease, and failed heart transplant. Multiple-organ transplant was performed in 25 of 313 patients (8%) (heart, liver, and kidney in 14 patients; heart and liver in 9 patients; and heart and kidney in 2 patients) and was particularly common in patients with amyloidosis (10 of 33 patients [30%]).
RESULTS

From
Perioperative neurologic complications occurred in 61 of 313 patients (19%); perioperative neurologic diseases are listed in Table 2 . There was a difference in com- Abbreviation: CI, confidence interval. a Miscellaneous causes included hypertrophic cardiomyopathy (n = 9), radiation cardiomyopathy (n = 9), valvular disease (n = 9), restrictive cardiomyopathy (n = 5), intractable ventricular tachycardia (n = 2), failed heart transplant (n = 2), postpartum cardiomyopathy (n = 2), cardiomyopathy after chemotherapy, (n = 3), cardiac hemochromatosis (n = 1), cardiomyopathy with Becker muscular dystrophy (n = 1), family history of sudden death (n = 1), endocardial fibroelastosis (n = 1), and giant cell myocarditis (n = 1).
WWW.ARCHNEUROL.COM 227 plication frequency between groups of causes (P =.004), with more complications in the group of miscellaneous causes of heart failure ( Table 2) . Common complications were delirium or encephalopathy (9%), cerebrovascular complications (5%), and diseases of the peripheral nerves and muscles (4%). Seizure activity occurred in 8 patients and was related to encephalopathy (PϽ.001). Patients in the miscellaneous group were more likely to develop encephalopathy compared with other patients (8 of 46 patients [17%] vs 19 of 267 patients [7%], respectively; P = .02); they also tended to have more seizures (P=.10). Other perioperative complications were equally divided between groups of causes. The proportion of patients with perioperative neurologic complications rose from 19% in 1988 to 1993 to 30% in 2000 to 2006 (P = .003) (Figure) , caused by increasing numbers of encephalopathy (P = .003). Fourteen of 313 patients (5%) died in the perioperative period, at a median (IQR) of 5 (1-44) days after transplant.
Neuroimaging was performed in 18 of 27 patients with perioperative encephalopathy. Cranial computed tomography was performed in 12 patients, magnetic resonance imaging was done in 11 patients, and 5 patients had both computed tomography and magnetic resonance imaging performed. Results of neuroimaging were no abnormalities (n = 6), posterior reversible leukoencephalopathy (n=3), remote cerebral infarction (n=3), cerebral ischemic small-vessel disease (n=2), cerebral infarction (n = 1), cerebral hemorrhage (n = 1), meningioma (n=1), and sinusitis (n=1).
Follow-up was complete for 306 of 313 patients (98%); 9 patients were lost to follow-up after 1 (n=4), 2 (n=1), 5 (n=1), and 6 (n=3) years after transplant. During the studied period, 95 of 313 patients (30%) died and the median (IQR) clinical follow-up was 5.5 (2.2-9.9) years.
Step In multivariate analysis, perioperative cerebrovascular complications were associated with 1-year mortality (HR, 4.17; 95% CI, 1.04-16.76; P = .04). Perioperative delirium or encephalopathy, diseases of peripheral nerves and muscles, and seizures were not related to 1-year mortality (P Ͼ.79).
Perioperative cerebrovascular complications occurred in 15 patients, with a median (IQR) age of 50 (41-59) years (Table 3) . Clinical manifestations were focal neurologic abnormalities (n=11), failure to awaken (n=2), and seizures (n=2), and they occurred after the second postoperative day in 10 of 15 patients (67%). Additional risk factors such as mechanical support of the circulation, cardiac tamponade or arrest, or atrial fibrillation were present in 11 of 15 patients (73%). Death or persisting neurologic sequelae occurred in 5 of 15 patients (33%).
The most frequently prescribed immunosuppressive treatments were corticosteroids (100%), cyclosporine (98%), and azathioprine (89%). High proportions of patients developed complications considered directly related to immunosuppressive treatment, such as decrease of renal function (defined as iothalamate clearancesϽ50 mL/min on scintigraphic analysis; 224 of 313 patients [71%]) or de novo diabetes (71 of 313 patients [23%]). The use of tacrolimus and sirolimus increased over time, and 17% and 37% of patients, respectively, were switched from cyclosporine-based therapy to these newer classes of immunosuppressive drugs.
One or more neurologic events developed after the perioperative period (initial transplant admission) in 226 of 313 patients (72%) ( Table 4 ). The cumulative risk 15 years after transplant was 81% (Table 4 ). The most frequent neurologic events 15 years after transplant were depression (35%), pain or pain syndromes (37%), sleeping disorders (32%), polyneuropathy (26%), and cere- for the patients without sleeping disorders. Polyneuropathy was more likely to occur in the 33 patients with amyloidosis (HR, 7.78; 95% CI, 4.30-14.01; P Ͻ.001), with 55% of the patients with amyloidosis and 13% of the patients without amyloidosis incurring polyneuropathy.
Cerebrovascular events occurred in 29 of 313 patients (9%), with a cumulative incidence of 6%, 11%, and 14% at 5, 10, and 15 years, respectively. Infarction occurred in 19 patients, transient ischemic attack in 8 patients, and hemorrhage in 5 patients. The crude incidence of stroke was calculated to be 14 per 1000 personyears. Cerebrovascular events were more likely to occur in patients with heart failure of miscellaneous cause (HR, 3.60; 95% CI, 1.57-8.28; P =.002) and tended to happen more often in patients with a history of stroke or transient ischemic attack at baseline (HR, 2.37; 95% CI, 0.96-5.85; P=.06). Four of 5 patients (80%) with cerebral hemorrhage were included in the group with heart failure of miscellaneous cause (P Ͻ .001).
To evaluate the association between neurologic complications and mortality, we included history of neurologic complications in the Cox model as timedependent predictors, together with the baseline predictors described earlier (serum creatinine level, amyloidal cause, history of hypertension, and female sex). Considered individually, central nervous system (CNS) infection (HR, 4.29; 95% CI, 1.69-10.91; P =.002), sei- a Prolonged mechanical support circulation (longer than the duration of the transplant procedure included extracorporal circulation before transplant (n = 1), a left ventricular-assisting device before transplant (n = 1), a left ventricular-assisting device after transplant (n = 1), a right ventricular-assisting device after transplant (n = 2), and a biventricular-assisting device after transplant (n = 2); 1 patient had a left ventricular-assisting device before transplant and a right ventricular-assisting device after transplant. Death  30  7  18  35  61  71  Any neurologic events a  72  44  62  78  81  81  Cerebrovascular diseases  9  3  6  11  14  14  Polyneuropathy  18  7  14  19  26  26  Seizures  4  2  4  5  5  5  Sleeping disorders  27  14  24  30  32  32  Cognitive decline  6  2  5  9  10  10  Pain  30  15  23  37  37  37  Depression b  28  14  23  31  35  39 a Miscellaneous included backbone fractures due to osteoporosis (n = 8), developmental delay in children (n = 2), definitive multiple sclerosis (n = 1), probable multiple sclerosis (n = 1), central pontine myelinolysis (n = 1), arteriovenous fistula (n = 1), and traumatic skull fracture (n = 1).
b Depression or anxiety was the sole neurologic event in 11 patients. zures (HR, 3.44; 95% CI, 1.33-8.85; P=.01) , and depression (HR, 1.81; 95% CI, 1.06-3.09; P = .03) were significant predictors, whereas cerebrovascular events (HR, 1.72; 95% CI, 0.89-3.32; P = .10), polyneuropathy (HR, 1.58; 95% CI, 0.90-2.78; P = .11), and pain (HR, 0.86; 95% CI, 0.48-1.52; P=.60) were not. Multivariately, only CNS infection (HR, 4.14; 95% CI, 1.74-11.2; P = .002) and seizure (HR, 3.56; 95% CI, 1.37-9.21; P = .009) were significant unless marginally significant predictors (PϽ.10) were included, in which case the model included CNS infection (HR, 3.83; 95% CI, 1.48-9.90; P=.006), depression (HR, 1.70; 95% CI, 0.99-2.91; P = .06), and seizure (HR, 2.84; 95% CI, 1.41-9.40; P = .007).
Death occurred during the study period in 95 of 313 patients (30%), with the cumulative incidence of death 61% at 15 years. Cause of death was neurologic in 12 of 95 patients (13%), including cerebrovascular disease in 5 patients, progressive multifocal leukoencephalopathy in 2 patients, and CNS aspergillosis with cerebral hemorrhage, Alzheimer disease, Lewy body dementia, cerebral astrocytoma, and central pontine myelinolysis each in 1 patient. Patients who died from progressive multifocal leukoencephalopathy underwent heart transplant on December 21, 1991, and February 25, 1995, and died after 37 and 18 months, respectively.
COMMENT
This study shows that heart transplant recipients are at high risk for neurologic complications (cumulative risk, 81% at 15 years). The most common major complication was stroke, and although the frequency of CNS infectious diseases was low, they were often fatal. Previous studies have reported substantially lower rates of neurologic complications in heart transplant recipients (7%-70%).
2-6 Our study was performed over 18 years and had a high rate of follow-up (97%).
Stroke was the major perioperative neurologic complication and was related to 1-year mortality. The prevalence of stroke in heart transplant recipients is higher compared with that in patients undergoing coronary artery bypass grafting 7 or with other transplant populations, such as liver and bone marrow transplant recipients. 8, 9 Previously reported rates of perioperative cerebrovascular complications range from 4% to 43%, [2] [3] [4] [5] [6] and the high 1-year survival in our study (93%) might be related to the relatively low proportion of patients with perioperative cerebrovascular complications. The 1-year mortality in our patients is much higher compared with the normal population. 10 Most of these patients presented with focal neurologic signs occurring after the second day, particularly in patients with risk factors such as mechanical support of the circulation, cardiac tamponade or arrest, or atrial fibrillation, suggesting that cerebral ischemic events after heart transplant are attributable to preoperative or postoperative cardiac dysfunction.
Heart transplant recipients were at high risk for cerebrovascular events in follow-up (cumulative risk, 14%). The crude incidence of stroke was 14 per 1000 personyears, which is a 10-fold increase of risk compared with the normal population. 11 Stroke was more likely to occur in patients with heart failure of miscellaneous cause. This miscellaneous group included patients with valvular disease. A previous study identified this group at risk for cerebrovascular diseases after heart transplant 6 ; however; strokes described in that study were ischemic, whereas in our study cerebral hemorrhage predominated in this group.
The rate of delirium or encephalopathy was 9%, which is comparable with bone marrow transplant but considerably lower than with liver transplant. 8, 9 Encephalopathy was transient in all of the patients, and neuroimaging showed structural lesions in only 2 of 27 patients. Three patients had drug-induced posterior reversible leukoencephalopathy. The prevalence of encephalopathy increased over time, and this was related to increasing numbers of heart failure of miscellaneous cause. Although the retrospective design precludes firm conclusions, this group can be regarded as a high-risk group with more acute and complicated disease and therefore at higher risk for perioperative encephalopathy.
Sleeping disorders were present in many patients. Sleep apnea syndrome has been described in 25% to 40% of patients with chronic heart failure and may persist after heart transplant. 12 A prospective study using polysomnography, sleep survey questionnaires, and health survey questionnaires showed sleeping disorders in 36% of heart transplant recipients. 13 High rates of sleeping disorders also occur in kidney transplant recipients and have been related to male sex, obesity, use of hypnotic drugs, and comorbidity. 14 Our study has 2 limitations. First, outcome events were recorded according to the judgment of the treating physician. Therefore, it is unclear to what extent these data represent a true evaluation of their number and nature. Second, an unknown proportion of neurologic events may have nothing to do with the cardiac transplant. Neurologic complications in the cardiac transplant population can be regarded as a complex interaction between pretransplant risk factors, a complicated surgical procedure, and several postneurosurgical factors (ie, immunosuppressive regimens).
In conclusion, perioperative neurologic complications are frequent in heart transplant recipients, but most are inconsequential. Perioperative stroke is the most important neurologic complication affecting survival in the first year after heart transplant. Central nervous system infections are the strongest independent predictors of mortality in the longer term, although stroke remains highly prevalent. 
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